Sutro Biopharma (STRO) Stock Price, News & Analysis

Company Overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.80 to $0.80
• 50-Day Range: $0.77 to $2.12
• 52-Week Range: $0.76 to $6.13
• Volume: 2,550 shs
• Average Volume: 972,712 shs
• Market Capitalization: $64.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.63
• Consensus Rating: Hold

Sutro Biopharma Stock Analysis - MarketRank™

Sutro Biopharma scored higher than 83% of companies evaluated by MarketBeat, and ranked 172nd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Sutro Biopharma has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Sutro Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Sutro Biopharma are expected to decrease in the coming year, from ($2.92) to ($2.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sutro Biopharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sutro Biopharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sutro Biopharma has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.75% of the float of Sutro Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sutro Biopharma has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Sutro Biopharma has recently increased by 1.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sutro Biopharma does not currently pay a dividend.

Dividend Growth

Sutro Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.70

Percentage of Shares Shorted

5.75% of the float of Sutro Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sutro Biopharma has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Sutro Biopharma has recently increased by 1.13%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

Sutro Biopharma has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Sutro Biopharma this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Sutro Biopharma is held by insiders.

Percentage Held by Institutions

96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STRO Stock Analysis - Frequently Asked Questions

How have STRO shares performed this year?

Sutro Biopharma's stock was trading at $1.84 at the beginning of the year. Since then, STRO stock has decreased by 58.1% and is now trading at $0.7703.
View the best growth stocks for 2025 here.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) posted its earnings results on Thursday, March, 13th. The company reported ($2.96) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $2.10. The business earned $14 million during the quarter, compared to analyst estimates of $10.44 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 101.89% and a negative net margin of 77.01%.

When did Sutro Biopharma IPO?

Sutro Biopharma (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's top institutional investors include Suvretta Capital Management LLC (9.05%), Vestal Point Capital LP (3.12%), Point72 Asset Management L.P. (2.66%) and MPM Bioimpact LLC (2.62%). Insiders that own company stock include Nicki Vasquez and Brunilda Shtylla.
View institutional ownership trends.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD).

Company Calendar

• Last Earnings: 3/13/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STRO
• CIK: 1382101
• Web: www.sutrobio.com
• Phone: (650) 392-8412
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.63
• High Stock Price Target: $17.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +760.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-106,790,000.00
• Net Margins: -77.01%
• Pretax Margin: -67.18%
• Return on Equity: -101.89%
• Return on Assets: -28.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.09
• Quick Ratio: 3.09

Sales & Book Value

• Annual Sales: $62.04 million
• Price / Sales: 1.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.45 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 82,459,000
• Free Float: 77,594,000
• Market Cap: $63.52 million
• Optionable: Optionable
• Beta: 1.22